Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Metabotropic glutamate receptor 2 | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Onchocerca volvulus | Golgi-associated plant pathogenesis-related protein 1 homolog | Metabotropic glutamate receptor 2 | 872 aa | 884 aa | 35.3 % |
Loa Loa (eye worm) | hypothetical protein | Metabotropic glutamate receptor 2 | 872 aa | 822 aa | 21.2 % |
Onchocerca volvulus | Cell death abnormality protein 8 homolog | Metabotropic glutamate receptor 2 | 872 aa | 883 aa | 43.3 % |
Onchocerca volvulus | Metabotropic glutamate receptor 2 | 872 aa | 774 aa | 20.4 % | |
Schistosoma mansoni | metabotropic glutamate receptor | Metabotropic glutamate receptor 2 | 872 aa | 892 aa | 26.9 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Brugia malayi | metabotropic glutamate receptor subtype 5a (mGluR5a), putative | 0.0055 | 0.0243 | 0.1262 |
Brugia malayi | Pax transcription factor protein 2 | 0.0233 | 0.1925 | 1 |
Brugia malayi | Metabotropic glutamate receptor precursor. | 0.0061 | 0.0298 | 0.1546 |
Wolbachia endosymbiont of Brugia malayi | acetylornithine transaminase protein | 0.0154 | 0.1179 | 0.5 |
Toxoplasma gondii | ornithine aminotransferase, mitochondrial precursor, putative | 0.0154 | 0.1179 | 0.5 |
Mycobacterium tuberculosis | Probable aminotransferase | 0.1083 | 1 | 1 |
Echinococcus multilocularis | ornithine aminotransferase | 0.0154 | 0.1179 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0075 | 0.0432 | 0.0824 |
Mycobacterium tuberculosis | Adenosylmethionine-8-amino-7-oxononanoate aminotransferase BioA | 0.1083 | 1 | 1 |
Plasmodium vivax | ornithine aminotransferase, putative | 0.0154 | 0.1179 | 0.5 |
Echinococcus multilocularis | ornithine aminotransferase | 0.0154 | 0.1179 | 1 |
Schistosoma mansoni | ornithine--oxo-acid transaminase | 0.0154 | 0.1179 | 1 |
Loa Loa (eye worm) | pax transcription factor protein 2 | 0.0233 | 0.1925 | 1 |
Echinococcus multilocularis | Aminotransferase class III | 0.0154 | 0.1179 | 1 |
Schistosoma mansoni | metabotropic glutamate receptor | 0.0051 | 0.0203 | 0.1725 |
Mycobacterium ulcerans | adenosylmethionine-8-amino-7-oxononanoate aminotransferase | 0.1083 | 1 | 1 |
Echinococcus multilocularis | metabotropic glutamate receptor 5 | 0.0075 | 0.0432 | 0.234 |
Echinococcus granulosus | ornithine aminotransferase | 0.0154 | 0.1179 | 1 |
Echinococcus granulosus | metabotropic glutamate receptor 5 | 0.0075 | 0.0432 | 0.234 |
Trichomonas vaginalis | acetylornithine aminotransferase, putative | 0.1083 | 1 | 0.5 |
Schistosoma mansoni | metabotropic glutamate receptor 2 3 (mglur group 2) | 0.0069 | 0.0377 | 0.3198 |
Onchocerca volvulus | 0.0233 | 0.1925 | 0.5 | |
Echinococcus granulosus | Aminotransferase class III | 0.0154 | 0.1179 | 1 |
Chlamydia trachomatis | glutamate-1-semialdehyde-2,1-aminomutase | 0.0154 | 0.1179 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.1083 | 1 | 1 |
Plasmodium falciparum | ornithine aminotransferase | 0.0154 | 0.1179 | 0.5 |
Brugia malayi | 4-aminobutyrate aminotransferase, mitochondrial precursor | 0.0154 | 0.1179 | 0.6124 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
%max (binding) | Positive allosteric modulation activity at rat mGlu2R expressed in HEK293 cells co-expressing GIRK channels by thallium flux assay relative to glutamate | ChEMBL. | 23009245 | |
EC50 (binding) | > 5 uM | Positive allosteric modulation activity at rat mGlu2R expressed in HEK293 cells co-expressing GIRK channels by thallium flux assay | ChEMBL. | 23009245 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.